Results 51 to 60 of about 2,223,573 (201)

Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck [PDF]

, 2008
Introduction: Gefitinib, an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces growth arrest in squamous cancer cell carcinoma of head and neck (SCCHN) cell lines mainly by blocking cells in G1 and preventing them ...
Romano, Carmela
core   +1 more source

Screening and Identification of MicroRNAs Related to Acquired Gefitinib-resistance 
in Lung Adenocarcinoma Cell Lines

Chinese Journal of Lung Cancer, 2011
Background and objective Acquired gefitinib-resistance was closely related to inefficiency of EGFR-TKI treatment in lung adenocarcinoma. However, it was not clear that how microRNAs influenced the acquired gefitinib-resistance in lung adenocarcinoma. The
Xuebo QIN, Bin LIU, Yang LI, Jiacong YOU, Qinghua ZHOU   +4 more
doaj   +1 more source

Analysis of the mechanisms of resistance to Epidermal growth factor receptor inhibitors and development of multiple targeted strategies [PDF]

, 2008
Background. Primary and acquired resistance to selective Epidermal growth factor receptor (EGFR) inhibitors remains the most significant obstacle to the success of these targeted agents in cancer therapy.
Rosa, Roberta
core   +1 more source

Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells 
via ROS/Sirt3/SOD2 Pathway

Chinese Journal of Lung Cancer, 2023
Background and objective Epidermal growth factor receptor (EGFR) gene mutations are the most common driver mutations in non-small cell lung cancer (NSCLC).
Yawan ZI, Ke LIAO, Hong CHEN
doaj   +1 more source

Pharmacological modulation and manipulation of cancer drug resistance [PDF]

, 2010
The aim of this project was to investigate pharmacological methods of overcoming resistance in cancer. Novel compounds, targeted therapies and non-steroidal anti-inflammatory drugs (NSAIDs) were examined for their potential to modulate and manipulate ...
Devery, Aoife
core   +2 more sources

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. [PDF]

, 2010
PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC).
Hirofumi Nakano, Nagashima, Seiji, Tsukamoto, Kazuhiro, Fukuda, Minoru, Katsumi Nakatomi, Doi, Seiji, Takatani, Hiroshi, Shigeru Kohno, Seiji Nagashima, Minoru Fukuda, Nakano, Hirofumi, Seiji Doi, Mineyo Takasu, Kazuhiro Tsukamoto, Yoichi Nakamura, Nakamura, Yoichi, Nanae Tomonaga, Hiroshi Soda, Hiroshi Takatani, Nakatomi, Katsumi, Tomayoshi Hayashi, Takasu, Mineyo, Tomonaga, Nanae, Kohno, Shigeru, Soda, Hiroshi, Yamaguchi, Hiroyuki, Hayashi, Tomayoshi, Hiroyuki Yamaguchi   +27 more
core   +1 more source

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer

Cell Death and Disease, 2021
Lung cancer is one of the most aggressive cancers with poor prognosis and high resistance rate. The family of signal transducer and activator of transcriptions (STATs) appears to modulate resistance in non-small cell lung cancer (NSCLC). In this work, we
Zhe Liu, Liang Ma, Yiming Sun, Wenying Yu, Xue Wang   +4 more
doaj   +1 more source

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus [PDF]

Clinical Cancer Research, 2007
Abstract Purpose: Ten percent of U.S. patients with non–small cell lung cancer experience partial radiographic responses to erlotinib or gefitinib. Despite initial regressions, these patients develop acquired resistance to erlotinib or gefitinib.
Gregory J, Riely, Mark G, Kris, Binsheng, Zhao, Tim, Akhurst, Daniel T, Milton, Erin, Moore, Leslie, Tyson, William, Pao, Naiyer A, Rizvi, Lawrence H, Schwartz, Vincent A, Miller   +10 more
openaire   +2 more sources

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib

Thoracic Cancer, 2021
Background Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) is an important regulator of epithelial‐mesenchymal transition (EMT) and is involved in the maintenance of cancer stem cells (CSCs) via miR‐200c and BMI1 pathway.
Fariz Nurwidya, Fumiyuki Takahashi, Wira Winardi, Ken Tajima, Yoichiro Mitsuishi, Akiko Murakami, Isao Kobayashi, Takeshi Nara, Muneaki Hashimoto, Motoyasu Kato, Moulid Hidayat, Kentaro Suina, Daisuke Hayakawa, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Toshifumi Yae, Naoko Shimada, Yasuko Yoshioka, Shinichi Sasaki, Kazuhisa Takahashi   +20 more
doaj   +1 more source

Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib

Biomedicine & Pharmacotherapy, 2012
Gefitinib, an EGFR receptor tyrosine kinase inhibitor, is approved for clinical use in the treatment of non-small cell lung cancer (NSCLC), but the emergence of mutations resistant to these inhibitors, such as T790M, has become a clinical problem. According to statistics, female patients, the presence of adenocarcinoma or non-smokers experienced a ...
Ruitong, Xu, Hua, Shen, Renhua, Guo, Jing, Sun, Wen, Gao, Yongqian, Shu   +5 more
openaire   +2 more sources